• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • AI Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • AI Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Graphic of a puzzle depicting both the US and Chinese flags with missing pieces bridging the two together
Favicon Fierce Biotech

Treasury COINS rules add biotech, spares China licensing deals

Despite the sweeping scope of the ban covering various drug modalities, biopharma business development teams can breathe a measured sigh of relief.
Angus Liu Oct 22, 2026 11:36pm
Podcast
The Next Chapter for AI in Clinical Trials

The Next Chapter for AI in Clinical Trials

Brought to you by Saama
Roches headquarters in Basel sunset in the background

Vabysmo shows signs of recovery as Roche gears up for busy 2027

Oct 22, 2026 11:20am
Why Are 53 of Phase 2 and 3 Trials Delayed A Redesign Is Overdue

Why Are 53% of Phase 2 and 3 Trials Delayed? A Redesign Is Overdue

Brought to you by Bain & Company
ESMO AstraZeneca

AZ lands 5th Ultomiris indication in kidney disease IgAN

Oct 22, 2026 11:15am
China

Esteve pledges $80M to overhaul its CDMO operations in China

Oct 22, 2026 10:52am
More News

Pfizer's cost savings drive touches jobs at US, Europe plants

Oct 22, 2026 9:32am

Roivant eyes Humira's throne in NIU after Lisraya ph. 3 win

Oct 22, 2026 8:04am

AbbVie pumps up the case for early subcutaneous Parkinson’s care

Oct 22, 2026 6:32am

Otsuka hit with marketing breaches after event organizer blunder

Oct 22, 2026 2:23am
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings